Webinar 3:
Thursday, March 26, 2009
12 pm ET • 90 minutes
Is There a Business Model for Companion Diagnostics?

A biomarker may ultimately become linked to a diagnostic product opportunity — as a predictive test to select patients more likely to respond to a drug or class of drugs, or as a way to monitor a response to one. But diagnostics development costs are soaring with greater demands for validation from prospective clinical trials, and pharma companies have been reluctant to support these efforts. Where are diagnostics companies turning for support and funding? Which high-value opportunities can sustain a business? Is collaboration the answer, and if so, in what form?

FEATURING:

Mickey Urdea CEO Tethys Bioscience	Kristin Pothier Vice President Health Advances (moderator)	Rosanne Welcher, PhD, MBA General Manager & VP, R&D The Dako Group
Iain Miller Senior Director, Oncology Strategy and Theranostics BioMérieux

______________________________________________________________________

Join us for a thought-provoking analysis of this evolving concept! Grab your team, a phone and a computer with Web access (that last one's optional). No travel required.

Audio recording only: $499

REGISTER

Register for the live webinar, the live webinar PLUS the audio recording or the audio recording only!

Back to top
______________________________________________________________________

FDC-Windhover
P.O. Box 7247
Philadelphia, PA 19101-9257
* Tel: +1 (800) 332-2181
* Fax: +1 (908) 547-2165